A multicentre trial with topotecan, mitoxantrone and cytarabine in patients with relapsed or refractory AML or CML in blast crisis - Interim results.

被引：0
|
作者：
Hoechsmann, B
Doehner, H
Ganser, A
Heil, G
Denzlinger, C
Einsele, H
Duerk, H
Raghavachar, A
Hoelzer, D
Bergmann, L
机构：
[1] Univ Ulm, Ulm, Germany
[2] MHH, Hannover, Germany
[3] Univ Tubingen, Tubingen, Germany
[4] Sankt Marien Hosp, Hamm, Germany
[5] Klinikum Wuppertal, Wuppertal, Germany
[6] Univ Frankfurt, D-6000 Frankfurt, Germany
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4564
引用
收藏
页码：213B / 213B
页数：1
相关论文
共 50 条
  • [41] Pre-Clinical and Interim Results of a Phase II Trial of Perifosine In Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Friedman, Daphne R.
    Davis, Patricia H.
    Lanasa, Mark C.
    Moore, Joseph O.
    Gockerman, Jon P.
    Nelson, Taylor
    Bond, Karen M.
    Jiang, Ning
    Davis, Evan D.
    Allgood, Sallie D.
    Chen, Youwei
    Sportelli, Peter
    Weinberg, J. Brice
    BLOOD, 2010, 116 (21) : 768 - 769
  • [42] Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML).
    Mathisen, Michael
    Kantarjian, Hagop
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Ravandi, Farhad
    Kadia, Tapan M.
    Daver, Naval Guastad
    O'Brien, Susan Mary
    Dorkhom, Stephan Joseph
    Pierce, Sherry
    Lira, Cynthia
    Cortes, Jorge E.
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] A phase I/II study of induction chemotherapy with daunorubicin, cytarabine, topotecan, and etoposide (DATE) for de novo, relapsed or refractory AML, or AML arising from a previous phase of MDS in treatment of patients ages 16-75.
    Blaine, G
    Saba, HI
    Loughran, TP
    Balducci, L
    Chervenick, PA
    Djulbegovic, B
    Extermann, MT
    Jove, R
    Lush, R
    Moscinski, LC
    Sotomayor, EM
    Seshi, B
    Zuckerman, KS
    Sullivan, DM
    BLOOD, 2001, 98 (11) : 209B - 209B
  • [44] Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis
    Holkova, Beata
    Tombes, Mary Beth
    Shrader, Ellen
    Cooke, Sheryl S.
    Wan, Wen
    Sankala, Heidi
    Kmieciak, Maciej
    Roberts, John D.
    Garcia-Manero, Guillermo
    Grant, Steven
    BLOOD, 2011, 118 (21) : 1115 - 1115
  • [45] Gilteritinib prolongs survival in patients with FLT3-mutated relapsed/refractory AML: phase 3 ADMIRAL trial results
    Perl, Alexander E.
    Martinelli, Giovanni
    Cortes, Jorge E.
    Neubauer, Andreas
    Berman, Ellin
    Paolini, Stefania
    Montesinos, Pau
    Baer, Maria R.
    Larson, Richard A.
    Ustun, Celalettin
    Fabbiano, Francesco
    Di Stasi, Antonio
    Stuart, Robert
    Olin, Rebecca
    Kasner, Margaret
    Ciceri, Fabio
    Chou, Wen-Chien
    Podoltsev, Nikolai
    Recher, Christian
    Yokoyama, Hisayuki
    Hosono, Naoko
    Yoon, Sung-Soo
    Lee, Je-Hwan
    Pardee, Timothy
    Fathi, Amir T.
    Liu, Chaofeng
    Liu, Xuan
    Bahceci, Erkut
    Levis, Mark J.
    SWISS MEDICAL WEEKLY, 2019, 149 : 3S - 4S
  • [46] Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
    Middeke, J. M.
    Herbst, R.
    Parmentier, S.
    Bug, G.
    Haenel, M.
    Stuhlers, G.
    Schaefer-Eckart, K.
    Roester, W.
    Klein, S.
    Bethge, W.
    Bitz, U.
    Buettner, B.
    Knoth, H.
    Alakel, N.
    Schaich, M.
    Morgner, A.
    Kramer, M.
    Sockel, K.
    von Bonin, M.
    Stoelzel, F.
    Platzbecker, U.
    Roellig, C.
    Thiede, C.
    Ehninger, G.
    Bornhaeuser, M.
    Schetelig, J.
    LEUKEMIA, 2016, 30 (02) : 261 - 267
  • [47] Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
    J M Middeke
    R Herbst
    S Parmentier
    G Bug
    M Hänel
    G Stuhler
    K Schäfer-Eckart
    W Rösler
    S Klein
    W Bethge
    U Bitz
    B Büttner
    H Knoth
    N Alakel
    M Schaich
    A Morgner
    M Kramer
    K Sockel
    M von Bonin
    F Stölzel
    U Platzbecker
    C Röllig
    C Thiede
    G Ehninger
    M Bornhäuser
    J Schetelig
    Leukemia, 2016, 30 : 261 - 267
  • [48] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
    Greenberg, PL
    Lee, SJ
    Advani, R
    Tallman, MS
    Sikic, BI
    Letendre, L
    Dugan, K
    Lum, B
    Chin, DL
    Dewald, G
    Paietta, E
    Bennett, JM
    Rowe, JM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1078 - 1086
  • [49] Safety and activity of KOS-953 in patients with relapsed refractory multiple myeloma (MM): Interim results of a phase 1 trial.
    Richardson, PG
    Chanan-Khan, AA
    Alsina, M
    Doss, D
    Landrigan, B
    Kettner, D
    Albitar, M
    Mitsiades, C
    Cropp, GF
    Johnson, RG
    Hannah, AL
    Anderson, KC
    BLOOD, 2005, 106 (11) : 109A - 109A
  • [50] Dexamethasone, cytarabine and oxaliplatin (DHAX) in relapsed or refractory non-Hodgkin's lymphoma patients: Results of an ongoing phase II trial.
    Chau, I
    Cunningham, D
    Hill, M
    Catovsky, D
    BLOOD, 2000, 96 (11) : 140A - 140A
12345